SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. You have free access to this content1
    Jia-Horng Kao, HBeAg-positive chronic hepatitis B: why do I treat my patients with pegylated interferon?, Liver International, 2014, 34,
  2. 2
    Jiezuan Yang, Jiajia Chen, Ping Ye, Linfeng Jin, Wei Wu, Guoping Sheng, Lan-Juan Li, HBsAg as an important predictor of HBeAg seroconversion following antiviral treatment for HBeAg-positive chronic hepatitis B patients, Journal of Translational Medicine, 2014, 12, 1, 183

    CrossRef

  3. 3
    Guangjun Song, Huiying Rao, Bo Feng, Lai Wei, Prediction of spontaneous HBeAg seroconversion in HBeAg-positive chronic hepatitis B patients during the immune clearance phase, Journal of Medical Virology, 2014, 86, 11
  4. 4
    Etsuro Orito, Chitomi Hasebe, Masayuki Kurosaki, Yukio Osaki, Kouji Joko, Hiroshi Watanabe, Hiroyuki Kimura, Norihiro Nishijima, Atsunori Kusakabe, Namiki Izumi, Risk of hepatocellular carcinoma in cirrhotic hepatitis B virus patients during nucleoside/nucleotide analog therapy, Hepatology Research, 2014, 44, 13
  5. 5
    L. Boglione, J. Cusato, A. De Nicolò, G. Cariti, G. Di Perri, A. D'Avolio, Role of CYP27B1+2838 promoter polymorphism in the treatment of chronic hepatitis B HBeAg negative with PEG-interferon, Journal of Viral Hepatitis, 2014, 21, 12
  6. 6
    Lucio Boglione, Jessica Cusato, Sarah Allegra, Isabella Esposito, Francesca Patti, Giuseppe Cariti, Giovanni Di Perri, Antonio D’Avolio, Role of IL28-B polymorphisms in the treatment of chronic hepatitis B HBeAg-negative patients with peginterferon, Antiviral Research, 2014, 102, 35

    CrossRef

  7. You have free access to this content7
    L. Boglione, A. D'Avolio, G. Cariti, M. G. Milia, M. Simiele, A. Nicolò, V. Ghisetti, G. Di Perri, Sequential therapy with entecavir and PEG-INF in patients affected by chronic hepatitis B and high levels of HBV-DNA with non-D genotypes, Journal of Viral Hepatitis, 2013, 20, 4
  8. 8
    Stephanos J. Hadziyannis, Dimitrios Vassilopoulos, Emilia Hadziyannis, Antiviral Agents, 2013,

    CrossRef

  9. 9
    Yu Xiang, Shifeng Huang, Jirong Xia, Diqing Ye, Pu Chen, Liping Zhang, Characterization of Hepatitis B Virus Molecular Genotypes in Chongqing and Quantitative Serological Markers in Patients during Natural Phases of Chronic Hepatitis B Infection, Intervirology, 2012, 55, 1, 68

    CrossRef

  10. 10
    Fayaz A. Handoo, Hamdan AlGhamdi, Faisal M. Sanai, Ibrahim H. Altraif, Interferon-based Therapy for e-antigen Negative Chronic Hepatitis B Virus Infection, Current Hepatitis Reports, 2012, 11, 4, 263

    CrossRef

  11. 11
    Stephanos J. Hadziyannis, Dimitrios Vassilopoulos, What Should Be the Endpoints of Oral Therapy in HBeAg-positive Versus HBeAg-negative Patients with Chronic Hepatitis B, Current Hepatitis Reports, 2012, 11, 2, 65

    CrossRef

  12. 12
    Judit Gervain, A HBV-DNS-titer és a HBsAg-szint-változás jelentősége krónikus B hepatitis kezelése során, Orvosi Hetilap, 2011, 152, 22, 866

    CrossRef

  13. You have free access to this content13
    Milan J. Sonneveld, Harry L. A. Janssen, Chronic hepatitis B: peginterferon or nucleos(t)ide analogues?, Liver International, 2011, 31,
  14. 14
    Pan Zhao, Weiwei Liu, Jun Zhao, Qun Guan, Comparison of the 48-week efficacy between entecavir and adefovir in HBeAg-positive nucleos(t)ide-naïve Asian patients with chronic hepatitis B: a meta-analysis, Virology Journal, 2011, 8, 1, 75

    CrossRef

  15. 15
    Li-Chun Wang, En-Qiang Chen, Jing Cao, Li Liu, Li Zheng, Da-Jiang Li, Lu Xu, Xue-Zhong Lei, Cong liu, Hong Tang, De novo combination of lamivudine and adefovir versus entecavir monotherapy for the treatment of naïve HBeAg-negative chronic hepatitis B patients, Hepatology International, 2011, 5, 2, 671

    CrossRef

  16. 16
    Elena Vezali, Alessio Aghemo, Pietro Lampertico, Massimo Colombo, Does interferon therapy prevent hepatocellular carcinoma in patients with chronic viral hepatitis?, Clinics and Research in Hepatology and Gastroenterology, 2011, 35, 6-7, 455

    CrossRef

  17. 17
    Natravis Cox, Hans Tillmann, Emerging pipeline drugs for hepatitis B infection, Expert Opinion on Emerging Drugs, 2011, 16, 4, 713

    CrossRef

  18. 18
    Vincenza Calvaruso, Antonio Craxì, Fibrosis in chronic viral hepatitis, Best Practice & Research Clinical Gastroenterology, 2011, 25, 2, 219

    CrossRef

  19. 19
    Michael Chang, Sammy Saab, Interferon for Hepatitis B: Which Populations Benefit the Most, Current Hepatitis Reports, 2011, 10, 4, 285

    CrossRef

  20. 20
    Jurriën G.P. Reijnders, Vincent Rijckborst, Milan J. Sonneveld, Sandra M.J. Scherbeijn, Charles A.B. Boucher, Bettina E. Hansen, Harry L.A. Janssen, Kinetics of hepatitis B surface antigen differ between treatment with peginterferon and entecavir, Journal of Hepatology, 2011, 54, 3, 449

    CrossRef

  21. 21
    Lucia Taramasso, Patrizia Caligiuri, Antonio Di Biagio, Bianca Bruzzone, Raffaella Rosso, Giancarlo Icardi, Claudio Viscoli, Lamivudine resistance mutations in European patients with hepatitis B and patients co-infected with HIV and hepatitis B, Journal of Medical Virology, 2011, 83, 11
  22. 22
    Chih-Lin Lin, Jia-Horng Kao, Recent advances in the treatment of chronic hepatitis B, Expert Opinion on Pharmacotherapy, 2011, 12, 13, 2025

    CrossRef

  23. You have free access to this content23
    V. Rijckborst, M. J. Sonneveld, H. L. A. Janssen, Review article: chronic hepatitis B – anti-viral or immunomodulatory therapy?, Alimentary Pharmacology & Therapeutics, 2011, 33, 5
  24. 24
    A. Gramenzi, E. Loggi, L. Micco, C. Cursaro, S. Fiorino, S. Galli, S. Gitto, C. Galli, G. Furlini, M. Bernardi, P. Andreone, Serum hepatitis B surface antigen monitoring in long-term lamivudine-treated hepatitis B virus patients, Journal of Viral Hepatitis, 2011, 18, 10
  25. 25
    Tatyana A. Shamliyan, James R. Johnson, Roderick MacDonald, Aasma Shaukat, Jian-Min Yuan, Robert L. Kane, Timothy J. Wilt, Systematic Review of the Literature on Comparative Effectiveness of Antiviral Treatments for Chronic Hepatitis B Infection, Journal of General Internal Medicine, 2011, 26, 3, 326

    CrossRef

  26. 26
    Derek Yu, Jenny Heathcote, Tenofovir in the treatment of chronic hepatitis B, Therapy, 2011, 8, 5, 527

    CrossRef

  27. 27
    Yaron Ilan, A fourth dimension in decision making in hepatology, Hepatology Research, 2010, 40, 12
  28. 28
    Maya Mouler Rechtman, Ofir Har-Noy, Iddo Bar-Yishay, Sigal Fishman, Yaarit Adamovich, Yosef Shaul, Zamir Halpern, Amir Shlomai, Curcumin inhibits hepatitis B virus via down-regulation of the metabolic coactivator PGC-1α, FEBS Letters, 2010, 584, 11, 2485

    CrossRef

  29. 29
    Milan J. Sonneveld, Vincent Rijckborst, Charles A. B. Boucher, Bettina E. Hansen, Harry L. A. Janssen, Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen–positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline, Hepatology, 2010, 52, 4
  30. 30
    Milan J. Sonneveld, Harry L. A. Janssen, Pros and Cons of Peginterferon Versus Nucleos(t)ide Analogues for Treatment of Chronic Hepatitis B, Current Hepatitis Reports, 2010, 9, 2, 91

    CrossRef

  31. 31
    Vincent Rijckborst, Harry L. A. Janssen, The Role of Interferon in Hepatitis B Therapy, Current Hepatitis Reports, 2010, 9, 4, 231

    CrossRef

  32. 32
    Gillian M. Keating, Peginterferon-α-2a (40 kD), Drugs, 2009, 69, 18, 2633

    CrossRef

  33. 33
    Maurizia R. Brunetto, Reply:, Hepatology, 2009, 50, 4
  34. 34
    Amir Shlomai, Yoav Lubelsky, Ofir Har-Noy, Yosef Shaul, The “Trojan horse” model-delivery of anti-HBV small interfering RNAs by a recombinant HBV vector, Biochemical and Biophysical Research Communications, 2009, 390, 3, 619

    CrossRef